BIO-Europe® 2017: Abivax CEO highlights pipeline assets, including lead HIV drug

Abivax CEO Dr. Hartmut Ehrlich talks to Scrip senior editor Lucie Ellis about the progress and next development steps for its lead clinical-stage molecule against HIV. Abivax is developing one of the first compounds, ABX464, to demonstrate an effect on human immunodeficiency (HIV) reservoirs in Phase II clinical trials. It is a first-in-class oral small anti-viral molecule, which blocks HIV replication through a unique mechanism of action. The French company is also developing ABX464 for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. A clinical study for the drug in IBD is currently enrolling patients.


for more information about BIO-EUROPE :

Press contacts

Caroline Carmagnol

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here